Theratechnologies IncNASDAQ:THTXView on Canadian Exchange
- LAST PRICE1.2000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.1400/ 10
- Ask / Lots1.4200/ 2
- Open / Previous Close--- / 1.2000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | THTX |
|---|---|---|
| 09:32 ET | 9387 | 1.241 |
| 09:33 ET | 300 | 1.16 |
| 09:46 ET | 1002 | 1.21 |
| 09:51 ET | 1004 | 1.17 |
| 10:06 ET | 150 | 1.2084 |
| 10:38 ET | 3511 | 1.18 |
| 10:44 ET | 600 | 1.18 |
| 10:47 ET | 100 | 1.1836 |
| 11:07 ET | 200 | 1.2 |
| 11:43 ET | 3000 | 1.1902 |
| 11:45 ET | 5973 | 1.2 |
| 11:50 ET | 700 | 1.185 |
| 11:52 ET | 700 | 1.18 |
| 11:56 ET | 100 | 1.18 |
| 01:13 ET | 500 | 1.19 |
| 01:29 ET | 100 | 1.2 |
| 02:45 ET | 200 | 1.1823 |
| 02:52 ET | 100 | 1.18 |
| 03:14 ET | 705 | 1.185 |
| 03:24 ET | 3500 | 1.195 |
| 03:30 ET | 300 | 1.195 |
| 03:33 ET | 200 | 1.19 |
| 03:46 ET | 250 | 1.1999 |
| 03:48 ET | 8193 | 1.21 |
| 03:50 ET | 100 | 1.21 |
| 03:57 ET | 4256 | 1.2 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Theratechnologies Inc | 76.8M | 0.0x | --- |
Company Information
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
Contact Information
- Headquarters
- 2015 Peel Street, 11th FloorMONTREAL, QC, Canada H3A 1T8
- Phone
- 514-336-7800
- Fax
- 514-331-9691
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $76.8M |
|---|---|
Revenue (TTM) | $117.9M |
Shares Outstanding | 46.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.75 |
EPS | $-0.13 |
Book Value | $-0.63 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 10.72% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
